| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Huang,Wen-Ying | Chairman | 1.99% | |
| Shen,Zhi-Long | Director | 16.55% | Taishan Buffalo No. 2 Biotech Venture Capital Limited Partnership |
| Huang,Rong-Yi | Director | 9.88% | Fubon Financial Holding Venture Capital Co., Ltd |
| Cai,Meng-Lin | Director | 3.27% | Orient Europharma Co., Ltd. |
| Zhuang,Zhi-Xuan | Director | 5.76% | President International Development Corp. |
| Su,Yu-Hui | Independent Director | 0.00% | |
| Kang,Zhao-Zhou | Independent Director | 0.00% | |
| Zhang,Zhen-Wu | Independent Director | 0.00% | |
| Liu,Jing-Ping | Independent Director | 0.00% |
Change Company Name to ANNJI PHARMACEUTICAL CO., LTD.
2024/05/17
Change Company Name to ANJI BIOTECH NEW DRUG CO., LTD. (FORMER NAME: ANJI BIOTECH NEW DRUG CO., LTD.)
2022/06/16
Change Capital to 2,000,000,000
2021/08/09
Change Capital to 1,000,000,000
2021/05/31
Change Person in Charge to Huang,Wen-Ying
2019/05/15
Change Capital to 300,000,000
2019/04/09
Change Person in Charge to Wang,Yi-Rong
2019/04/09
Change Company Name to ANNJI PHARMACEUTICAL CO., LTD.
2015/09/02
下載完整報告查看完整數據
| 項目 | 2024 | 2023 |
|---|---|---|
| Operating income | 96,448 | 143,530 |
| Operating cost | 87,556 | 125,087 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - |
| Operating gross profit (loss) | 8,892 | 18,443 |
| Unrealized profit (loss) on sales of goods | - | - |
| Realized profit (loss) on sales of goods | - | - |
| Operating gross profit (loss), net | 8,892 | 18,443 |
| Operating expenses | 369,033 | 287,065 |
| Other gain (loss), net | - | - |
| Operating profit (loss) | -360,141 | -268,622 |
| Non-operating income and expenses | 6,155 | -22,155 |
| Net profit (loss) before tax | -353,986 | -290,777 |
| Income tax expense (benefits) | 0 | 38,440 |
| Net profit (loss) of ongoing business for the current period | -353,986 | -329,217 |
| Profit (loss) of closed units | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - |
| Net profit (loss) for the current period | -353,986 | -329,217 |
| Other comprehensive profit (loss), net | 9,425 | 10,375 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - |
| Total comprehensive profit and loss for the current period | -344,561 | -318,842 |
| Net profit (loss) attributable to owners of parent company | - | -329,217 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | -318,842 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - |
| Basic earnings per share (yuan) | -3 | -4 |
| 項目 | 2024 | 2023 |
|---|---|---|
| Net cash inflow (outflow) from operating activities | - | -67,199 |
| Net cash inflows (outflows) from investing activities | - | -288,020 |
| Net cash inflow (outflow) from financing activities | - | 685,175 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | 0 |
| Increase (decrease) in cash and cash equivalents in the current period | - | 329,956 |
| Beginning balance of cash and cash equivalents | - | 267,900 |
| Ending balance of cash and cash equivalents | - | 597,856 |
| 項目 | 2024 | 2023 |
|---|---|---|
| Current asset | 743,800 | 918,821 |
| Non-current asset | 258,201 | 289,162 |
| Total asset | 1,002,001 | 1,207,983 |
| Current liability | 290,542 | 227,604 |
| Non-current liability | 49,362 | 55,339 |
| Total liability | 339,904 | 282,943 |
| share capital | 938,823 | 908,605 |
| Equity - secruity token | - | - |
| capital reserve | 961,072 | 909,672 |
| retained earning | -1,300,001 | -946,015 |
| Other equity | 62,203 | 52,778 |
| Treasury stock | - | - |
| Total equity attributable to owners of parent company | - | 925,040 |
| Equity attributable to former owner of business combination under common control | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - |
| Non-controlling interests | - | - |
| Total Equity | 662,097 | 925,040 |
| Share capital awaiting retirement (unit: share) | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 190,500 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 |
| Net asset value per share | 7 | 10 |
